Core Viewpoint - Agenus (AGEN) has experienced a decline of 7.9% over the past week, but the formation of a hammer chart pattern suggests potential support and a possible trend reversal in the future [1][2]. Technical Analysis - A hammer chart pattern indicates a minor difference between opening and closing prices, with a long lower wick, suggesting that the stock may have found support after a downtrend [3][4]. - The occurrence of a hammer pattern at the bottom of a downtrend signals that bears may have lost control, indicating a potential trend reversal [4]. Fundamental Analysis - There is rising optimism among Wall Street analysts regarding AGEN's future earnings, which enhances the prospects for a trend reversal [2][6]. - The consensus EPS estimate for the current year has increased by 7.4% over the last 30 days, indicating analysts' agreement on the company's potential for better earnings [7]. - AGEN holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [8].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Agenus Inc. Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (exact name of registrant as specified in its charter) For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 Indicate by check mark if the registrant is not required to file repor ...

Agenus Inc. (NASDAQ:AGEN) Q4 2024 Earnings Conference Call March 11, 2025 8:30 AM ET Company Participants Zack Armen - Head of Investor Relations, Corporate Development Garo Armen - Chairman and Chief Executive Officer Christine Klaskin - Vice President, Finance and Principal Financial and Accounting Officer Steven O'Day - Chief Medical Officer Robin Taylor - Chief Commercial Officer Conference Call Participants Emily Bodnar - H.C. Wainwright Mayank Mamtani - B. Riley Securities Operator Good morning and we ...

Agenus (AGEN) came out with a quarterly loss of $2.04 per share versus the Zacks Consensus Estimate of a loss of $2.36. This compares to loss of $2.60 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 13.56%. A quarter ago, it was expected that this biotechnology company would post a loss of $2.10 per share when it actually produced a loss of $3.17, delivering a surprise of -50.95%.Over the last four quarters, the company has su ...

Financial Performance - Agenus Inc. reported financial results for Q4 and the year ended December 31, 2024[6] - The company issued a press release on March 11, 2025, detailing its financial performance[6] - Specific financial metrics and user data were not provided in the available content[6]

Group 1 - Momentum investing contrasts with the traditional "buy low and sell high" strategy, focusing instead on "buying high and selling higher" to capitalize on fast-moving stocks [1] - Identifying the right entry point for trending stocks can be challenging, as they may lose momentum if future growth does not justify their high valuations [1] - A safer investment approach involves targeting bargain stocks that exhibit recent price momentum, utilizing tools like the Zacks Momentum Style Score [2] Group 2 - Agenus (AGEN) is highlighted as a strong candidate for investment, showing a four-week price change of 14.7%, indicating growing investor interest [3] - AGEN has demonstrated significant long-term momentum, with a 28.7% price increase over the past 12 weeks and a beta of 1.31, suggesting it moves 31% more than the market [4] - The stock has a Momentum Score of B, indicating a favorable time for investment to leverage its momentum [5] Group 3 - AGEN's upward trend in earnings estimate revisions has contributed to its Zacks Rank 2 (Buy), which is associated with strong momentum effects [6] - The stock is currently trading at a Price-to-Sales ratio of 0.57, indicating it is undervalued at 57 cents for each dollar of sales [6] - AGEN is positioned for further growth, with potential for fast-paced performance [7]

Company Performance - Agenus (AGEN) has returned approximately 27.7% year-to-date, significantly outperforming the average return of 5.6% for the Medical sector [4] - The Zacks Consensus Estimate for Agenus's full-year earnings has increased by 33.3% over the past three months, indicating improved analyst sentiment and a more positive earnings outlook [3] Industry Comparison - Agenus is part of the Medical - Biomedical and Genetics industry, which includes 512 stocks and currently ranks 73 in the Zacks Industry Rank. This industry has gained about 5% year-to-date, showing that Agenus is performing better than its peers [5] - In contrast, another Medical stock, Concentra Group (CON), has returned 18.8% year-to-date and belongs to the Medical Services industry, which is ranked 178 and has moved up by 2% this year [4][6] Zacks Rank - Agenus holds a Zacks Rank of 2 (Buy), which is indicative of its potential to outperform the market in the near term [3] - The Zacks Rank system emphasizes earnings estimates and revisions, highlighting stocks that are likely to beat the market over the next one to three months [3]

Core Viewpoint - Agenus (AGEN) has received an upgrade to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on the Zacks Consensus Estimate, which reflects EPS estimates from sell-side analysts for the current and following years [1][2]. - Changes in a company's future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with near-term stock price movements [4][6]. - Rising earnings estimates for Agenus indicate an improvement in the company's underlying business, which is expected to drive the stock price higher [5][10]. Zacks Rank System - The Zacks Rank stock-rating system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) to Zacks Rank 5 (Strong Sell) [7]. - Historically, Zacks Rank 1 stocks have generated an average annual return of +25% since 1988, demonstrating the effectiveness of the system [7]. Recent Performance of Agenus - For the fiscal year ending December 2024, Agenus is expected to earn -$12.84 per share, reflecting a year-over-year change of 7% [8]. - Over the past three months, the Zacks Consensus Estimate for Agenus has increased by 13.3%, indicating positive sentiment among analysts [8][10]. Conclusion - The upgrade of Agenus to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks based on estimate revisions, suggesting potential for market-beating returns in the near term [9][10].

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Agenus (AGEN) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.Agenus is one of 1010 individual stocks in the Medical sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector R ...

Core Viewpoint - Agenus (AGEN) has experienced significant selling pressure, resulting in a 41.6% decline in stock price over the past four weeks, but analysts anticipate improved earnings in the near future [1]. Group 1: Technical Analysis - The Relative Strength Index (RSI) for AGEN is currently at 16.18, indicating that the heavy selling may be exhausting, suggesting a potential rebound [5]. - AGEN's RSI reading of 32.579 as of November 8, 2023, indicates it is approaching oversold territory, which typically signals a possible price reversal [6]. Group 2: Earnings Estimates - There has been a strong consensus among sell-side analysts to raise earnings estimates for AGEN, leading to a 38.9% increase in the consensus EPS estimate over the last 30 days [7]. - An upward trend in earnings estimate revisions is generally associated with price appreciation in the near term [7]. Group 3: Analyst Ratings - AGEN currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a potential turnaround [8].